title: Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective.
abstract: OBJECTIVE
  The budgetary impact of adding ceftaroline fosamil to a hospital formulary for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) was evaluated.
  
  
  METHODS
  A three-year hospital budget impact model was constructed with three initial treatment options for ABSSSIs: ceftaroline fosamil, vancomycin plus aztreonam, and other vancomycin-containing regimens. The target population was hospitalized adult patients with an ABSSSI. Clinical cure rates with initial treatment were assumed to be similar to those from ceftaroline fosamil clinical trials. Patients who did not respond to initial treatment were assumed to be treated successfully with second-line antimicrobial therapy. Length of stay and cost per hospital day (by success or failure with initial treatment) were estimated based on a large database from more than 100 U.S. hospitals. Other model inputs included the annual number of ABSSSI admissions, projected annual case growth rate, proportion of ABSSSI target population receiving vancomycin-containing regimen, expected proportion of ABSSSI target population to be treated with ceftaroline fosamil, drug acquisition cost, cost of antibiotic administration, and cost of vancomycin monitoring. Sensitivity analysis using 95% confidence limits of clinical cure rates was also performed.
  
  
  RESULTS
  The estimated total cost of care for treating a patient with an ABSSSI was $395 lower with ceftaroline fosamil ($15,087 versus $15,482) compared with vancomycin plus aztreonam and $72 lower ($15,087 versus $15,159) compared with other vancomycin-containing regimens.
  
  
  CONCLUSIONS
  Model estimates indicated that adding ceftaroline fosamil to the hospital formulary would not have a negative effect on a hospital's budget for ABSSSI treatment.
authors.affiliation: Forest Research Institute, Jersey City, NJ 07311, USA. xing-yue.huang@frx.com
authors.forename: Xingyue
authors.initials: X
authors.lastname: Huang
authors.forename: Eric
authors.initials: E
authors.lastname: Beresford
authors.forename: Thomas
authors.initials: T
authors.lastname: Lodise
authors.forename: H David
authors.initials: HD
authors.lastname: Friedland
mesh_terms: D000208:Acute Disease; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D001398:Aztreonam / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D002511:Cephalosporins / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D004359:Drug Therapy, Combination; D004469:Economics, Hospital; D005572:Formularies, Hospital as Topic; D006801:Humans; D007902:Length of Stay / Q000191:economics; D018803:Models, Economic; D017192:Skin Diseases, Bacterial / Q000188:drug therapy / Q000191:economics* / Q000382:microbiology; D014640:Vancomycin / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D000097583:Ceftaroline
chemical_list: D000900:Anti-Bacterial Agents; D001398:Aztreonam; D002511:Cephalosporins; D014640:Vancomycin; D000097583:Ceftaroline